Identifying FUS amyotrophic lateral sclerosis disease signatures in patient dermal fibroblasts

Citations Over TimeTop 10% of 2024 papers

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, highly heterogeneous neurodegenerative disease, underscoring the importance of obtaining information to personalize clinical decisions quickly after diagnosis. Here, we investigated whether ALS-relevant signatures can be detected directly from biopsied patient fibroblasts. We profiled familial ALS (fALS) fibroblasts, representing a range of mutations in the fused in sarcoma (FUS) gene and ages of onset. To differentiate FUS fALS and healthy control fibroblasts, machine-learning classifiers were trained separately on high-content imaging and transcriptional profiles. "Molecular ALS phenotype" scores, derived from these classifiers, captured a spectrum from disease to health. Interestingly, these scores negatively correlated with age of onset, identified several pre-symptomatic individuals and sporadic ALS (sALS) patients with FUS-like fibroblasts, and quantified "movement" of FUS fALS and "FUS-like" sALS toward health upon FUS ASO treatment. Taken together, these findings provide evidence that non-neuronal patient fibroblasts can be used for rapid, personalized assessment in ALS.

Related Papers

• → Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis(2021)46 cited
• → Amyotrophic Lateral Sclerosis Sera Applied to Cultured Motor Neurons(1974)38 cited
• → Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis(2007)6 cited
• → Genetics of Amyotrophic Lateral Sclerosis(2014)4 cited
• Diagnosis and Treatment of Amyotrophic Lateral Sclerosis(2011)